医学
Wiskott-Aldrich综合征
噻替帕
氟达拉滨
环磷酰胺
布苏尔班
造血干细胞移植
干细胞
外科
移植
化疗
遗传学
生物化学
生物
基因
化学
作者
Anil Kumar Sharma,Neha Rastogi,Rohit Kapoor,Goutomi Chatterjee,Satya Prakash Yadav
标识
DOI:10.1097/mph.0000000000001841
摘要
Hematopoietic stem cell transplant (HSCT) is the only curative treatment modality for Wiskott-Aldrich syndrome. Haploidentical HSCT with posttransplant cyclophosphamide (PTCy) is an upcoming option in children with nonmalignant conditions. However, only few cases have been reported for Wiskott-Aldrich syndrome HSCT with PTCy approach. Here we report a 4-year-old boy, treated successfully by haploidentical HSCT with myeloablative conditioning (busulfan, fludarabine, and thiotepa) and PTCy. Posttransplant chimerism was fully donor. Of 13 cases (current case and other 12 published cases) 10 are alive and disease free after haploidentical HSCT with PTCy. Haploidentical HSCT with PTCy using myeloablative conditioning is feasible and safe.
科研通智能强力驱动
Strongly Powered by AbleSci AI